This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n18http://linked.opendata.cz/resource/domain/vavai/subjekt/
n12http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n14http://bibframe.org/vocab/
n11http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00669806%3A_____%2F12%3A10135327%21RIV14-MZ0-00669806/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00669806%3A_____%2F12%3A10135327%21RIV14-MZ0-00669806
rdf:type
skos:Concept n12:Vysledek
rdfs:seeAlso
http://www.nature.com/bmt/journal/v47/n5/pdf/bmt2011156a.pdf
dcterms:description
Oral cavity cooling (cryotherapy) provided during high-dose melphalan bolus or short-infusion administration contributes to local vasoconstriction, lower blood circulation, lower local cytotoxic drug exposure and significantly reduced oral mucositis (OM) incidence.1-3 OM is a significant posttransplant complication, and together with gut tissue damage and inflammation, caused by conditioning regimens, contributes to the development and pathogenesis of acute GVHD.4-6 The incidence of acute GVHD varies between 28 and 45% in the Flu/Mel-reduced intensity conditioning regimen comprising of fludarabine total dose 125-150mg/m2 and melphalan total dose 140-180mg/m2.1,7-9 We decided to analyze the impact of reduced OMincidence (reduced oral tissue damage) on acute GVHD, and analyzed 142 prospectively observed patients after Flu/Mel (fludarabine 30mg/m2 i.v. once daily for 4 days, melphalan 140mg/m2 i.v. one day before transplantation) allo-SCT performed at our institution from January 2005 to December 2010. Oral cavity cooling (cryotherapy) provided during high-dose melphalan bolus or short-infusion administration contributes to local vasoconstriction, lower blood circulation, lower local cytotoxic drug exposure and significantly reduced oral mucositis (OM) incidence.1-3 OM is a significant posttransplant complication, and together with gut tissue damage and inflammation, caused by conditioning regimens, contributes to the development and pathogenesis of acute GVHD.4-6 The incidence of acute GVHD varies between 28 and 45% in the Flu/Mel-reduced intensity conditioning regimen comprising of fludarabine total dose 125-150mg/m2 and melphalan total dose 140-180mg/m2.1,7-9 We decided to analyze the impact of reduced OMincidence (reduced oral tissue damage) on acute GVHD, and analyzed 142 prospectively observed patients after Flu/Mel (fludarabine 30mg/m2 i.v. once daily for 4 days, melphalan 140mg/m2 i.v. one day before transplantation) allo-SCT performed at our institution from January 2005 to December 2010.
dcterms:title
Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT
skos:prefLabel
Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT
skos:notation
RIV/00669806:_____/12:10135327!RIV14-MZ0-00669806
n12:predkladatel
n18:ico%3A00669806
n3:aktivita
n4:I
n3:aktivity
I
n3:cisloPeriodika
5
n3:dodaniDat
n6:2014
n3:domaciTvurceVysledku
n7:2591359 n7:4863712 n7:1203037 n7:9808108 n7:6662986
n3:druhVysledku
n19:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n11:predkladatel
n3:idSjednocenehoVysledku
157039
n3:idVysledku
RIV/00669806:_____/12:10135327
n3:jazykVysledku
n8:eng
n3:klicovaSlova
prevention; fludarabine; regimen; melphalan; Stem-cell transplantation
n3:klicoveSlovo
n16:Stem-cell%20transplantation n16:fludarabine n16:regimen n16:prevention n16:melphalan
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[D124FEE3A918]
n3:nazevZdroje
Bone Marrow Transplantation
n3:obor
n9:FD
n3:pocetDomacichTvurcuVysledku
5
n3:pocetTvurcuVysledku
5
n3:rokUplatneniVysledku
n6:2012
n3:svazekPeriodika
47
n3:tvurceVysledku
Svoboda, Tomáš Karas, Michal Koza, Vladimír Vokurka, Samuel Jungová, Alexandra
n3:wos
000303923500021
s:issn
0268-3369
s:numberOfPages
3
n14:doi
10.1038/bmt.2011.156